126.30
price down icon1.05%   -1.34
after-market Handel nachbörslich: 126.32 0.02 +0.02%
loading
Schlusskurs vom Vortag:
$127.64
Offen:
$127.95
24-Stunden-Volumen:
7.64M
Relative Volume:
1.29
Marktkapitalisierung:
$219.05B
Einnahmen:
$41.95B
Nettoeinkommen (Verlust:
$13.40B
KGV:
16.51
EPS:
7.65
Netto-Cashflow:
$6.35B
1W Leistung:
-4.79%
1M Leistung:
-2.98%
6M Leistung:
+9.94%
1J Leistung:
+12.33%
1-Tages-Spanne:
Value
$124.90
$128.62
1-Wochen-Bereich:
Value
$124.50
$132.61
52-Wochen-Spanne:
Value
$99.71
$140.84

Abbott Laboratories Stock (ABT) Company Profile

Name
Firmenname
Abbott Laboratories
Name
Telefon
(224) 667-6100
Name
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
Mitarbeiter
114,000
Name
Twitter
@AbbottNews
Name
Nächster Verdiensttermin
2025-01-22
Name
Neueste SEC-Einreichungen
Name
ABT's Discussions on Twitter

Vergleichen Sie ABT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Devices icon
ABT
Abbott Laboratories
126.30 219.05B 41.95B 13.40B 6.35B 7.65
Medical Devices icon
BSX
Boston Scientific Corp
99.22 146.43B 16.75B 1.85B 2.37B 1.25
Medical Devices icon
SYK
Stryker Corp
375.91 143.44B 22.60B 2.99B 3.49B 7.76
Medical Devices icon
MDT
Medtronic Plc
92.21 118.24B 33.20B 4.26B 5.47B 3.29
Medical Devices icon
EW
Edwards Lifesciences Corp
70.34 41.35B 5.72B 4.17B 259.90M 6.97

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-08 Eingeleitet Oppenheimer Outperform
2024-09-19 Eingeleitet Piper Sandler Overweight
2024-07-30 Herabstufung Edward Jones Buy → Hold
2024-05-30 Eingeleitet Goldman Buy
2023-07-21 Hochstufung Wolfe Research Underperform → Peer Perform
2023-05-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-04-20 Bestätigt Barclays Overweight
2023-04-20 Bestätigt Bernstein Outperform
2023-04-20 Bestätigt JP Morgan Overweight
2023-04-20 Bestätigt Raymond James Outperform
2023-04-20 Bestätigt UBS Buy
2023-04-20 Bestätigt Wolfe Research Underperform
2023-03-29 Eingeleitet UBS Buy
2022-10-26 Eingeleitet Mizuho Neutral
2022-10-18 Eingeleitet Barclays Overweight
2022-10-12 Eingeleitet Jefferies Hold
2022-07-06 Eingeleitet Wolfe Research Underperform
2022-03-02 Fortgesetzt BofA Securities Buy
2022-01-27 Bestätigt Credit Suisse Outperform
2022-01-27 Bestätigt Morgan Stanley Overweight
2022-01-27 Bestätigt Raymond James Outperform
2022-01-27 Bestätigt UBS Buy
2021-12-10 Eingeleitet RBC Capital Mkts Outperform
2021-10-27 Hochstufung Atlantic Equities Neutral → Overweight
2021-10-14 Eingeleitet Redburn Neutral
2021-05-25 Eingeleitet Barclays Overweight
2021-04-15 Eingeleitet Atlantic Equities Neutral
2021-01-28 Hochstufung BTIG Research Neutral → Buy
2020-09-11 Eingeleitet Wolfe Research Outperform
2020-06-01 Herabstufung Goldman Neutral → Sell
2020-03-05 Eingeleitet Citigroup Buy
2020-02-13 Eingeleitet Goldman Neutral
2020-02-06 Fortgesetzt BTIG Research Neutral
2020-01-02 Herabstufung Guggenheim Buy → Neutral
2019-06-13 Bestätigt BofA/Merrill Buy
2019-02-07 Bestätigt BofA/Merrill Buy
2019-01-02 Herabstufung Citigroup Neutral → Sell
2018-11-30 Hochstufung Goldman Neutral → Buy
2018-10-16 Eingeleitet Barclays Overweight
2018-06-27 Eingeleitet Bernstein Outperform
2018-01-30 Bestätigt Citigroup Neutral
2018-01-25 Bestätigt Stifel Buy
2018-01-25 Hochstufung William Blair Mkt Perform → Outperform
2018-01-03 Eingeleitet Evercore ISI Outperform
2018-01-02 Hochstufung JP Morgan Neutral → Overweight
2018-01-02 Hochstufung Morgan Stanley Equal-Weight → Overweight
2017-10-19 Bestätigt RBC Capital Mkts Outperform
2017-10-19 Bestätigt Stifel Buy
Alle ansehen

Abbott Laboratories Aktie (ABT) Neueste Nachrichten

pulisher
02:23 AM

US health agencies announce plan to strengthen infant formula supply and quality -March 18, 2025 at 02:23 pm EDT - Marketscreener.com

02:23 AM
pulisher
01:48 AM

Abbott Laboratories (ABT): Among the Best Diabetes Stocks to Buy According to Billionaires - Insider Monkey

01:48 AM
pulisher
12:00 PM

Decoding Abbott Laboratories's Options Activity: What's the Big Picture? - Benzinga

12:00 PM
pulisher
09:30 AM

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views? - Nasdaq

09:30 AM
pulisher
03:19 AM

Personalized Vitamins Market Top Players- BASF SE, Abbott Laboratories. Amway Corporation, Bayer AG, Caligenix. - openPR

03:19 AM
pulisher
Mar 17, 2025

Abbott's Narrow Economic Moat Rests on a Solid Product Portfolio - Morningstar

Mar 17, 2025
pulisher
Mar 17, 2025

Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock? - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Blood Typing Analysis Report 2024: Market Set to Surge to $6.50 Billion by 2034, PCR and Microarray Techniques Pave the Way - GlobeNewswire Inc.

Mar 17, 2025
pulisher
Mar 17, 2025

Abbott Stock Could Be On The Verge Of A Breakout — Here’s What Smart Money Sees (NYSE:ABT) - Seeking Alpha

Mar 17, 2025
pulisher
Mar 17, 2025

Reckitt’s Mead Johnson, Abbott to face new trial in US infant-formula case - just-food.com

Mar 17, 2025
pulisher
Mar 17, 2025

Abbott Laboratories Insiders Sell US$3.3m Of Stock, Possibly Signalling Caution - Yahoo Finance

Mar 17, 2025
pulisher
Mar 16, 2025

Abbott Laboratories' (NYSE:ABT) earnings growth rate lags the 15% CAGR delivered to shareholders - Simply Wall St

Mar 16, 2025
pulisher
Mar 16, 2025

Abbott Laboratories Basking In A Sharp Turn In Sentiment (NYSE:ABT) - Seeking Alpha

Mar 16, 2025
pulisher
Mar 15, 2025

Why Abbott Laboratories (ABT) Went Down On Thursday? - MSN

Mar 15, 2025
pulisher
Mar 15, 2025

Why Abbott Laboratories (ABT) Went Down On Friday? - Insider Monkey

Mar 15, 2025
pulisher
Mar 14, 2025

Abbott Labs, Reckitt Benckiser Shares Fall After New Ruling on Infant Formula Case - The Wall Street Journal

Mar 14, 2025
pulisher
Mar 14, 2025

Baby Formula Makers Abbott and Reckitt See Stocks Slide as Judge Allows Retrial - Investopedia

Mar 14, 2025
pulisher
Mar 14, 2025

In a setback for Abbott Laboratories, judge allows new trial in case over formula for premature infants - Chicago Tribune

Mar 14, 2025
pulisher
Mar 14, 2025

Judge Vacates Baby Formula Trial Win For Abbott, Mead - Law360

Mar 14, 2025
pulisher
Mar 14, 2025

‘A Manifest Injustice': Judge Who Sanctioned Abbott’s Counsel Grants New Infant Formula Trial - Law.com

Mar 14, 2025
pulisher
Mar 14, 2025

Sector Update: Health Care -March 14, 2025 at 03:29 pm EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

BofA keeps $150 target on Abbott Labs stock amid retrial news - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Abbott, Reckitt Fall as Judge Grants New Trial on Infant Formula - Bloomberg

Mar 14, 2025
pulisher
Mar 14, 2025

Abbott, Reckitt face new trial over premature infant formula - Reuters

Mar 14, 2025
pulisher
Mar 14, 2025

That baby formula trial Abbott and Reckitt won isn't over just yet - Crain's Chicago Business

Mar 14, 2025
pulisher
Mar 14, 2025

Judge orders retrial in Abbott, Reckitt infant formula case - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Citi maintains Abbott stock Buy rating, $160 target amid legal updates By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Is Abbott Laboratories (ABT) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 14, 2025
pulisher
Mar 14, 2025

Citi maintains Abbott stock Buy rating, $160 target amid legal updates - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Abbott, Reckitt face new trial over premature infant formula -March 14, 2025 at 11:09 am EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Positive Long-Term Outlook for Abbott Laboratories Despite Short-Term NEC Litigation Risks - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Abbott sends film crew to highlight partnership with Auburn Community Hospital - The Citizen

Mar 14, 2025
pulisher
Mar 14, 2025

Abbott stock falls following retrial order in infant formula case - Investing.com

Mar 14, 2025
pulisher
Mar 13, 2025

Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.

Mar 13, 2025
pulisher
Mar 13, 2025

Abbott (ABT) Stock Moves -0.3%: What You Should Know - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - MSN

Mar 13, 2025
pulisher
Mar 12, 2025

Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Glucose Biosensor Market Booming with Technological Advancements | Industry Insights Abbott Laboratories, - EIN News

Mar 12, 2025
pulisher
Mar 12, 2025

Here's Why We Think Abbott Laboratories (NYSE:ABT) Might Deserve Your Attention Today - Yahoo Finance

Mar 12, 2025
pulisher
Mar 11, 2025

OTC Consumer Health Market Positioned for Accelerated Growth with Johnson&Johnson, Abbott Laboratories, - EIN News

Mar 11, 2025
pulisher
Mar 11, 2025

EPD Expansion Supports Abbot Stock, Macro Issues Prevail - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Abbott Laboratories (NYSE:ABT) Given New $150.00 Price Target at Bank of America - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment - Benzinga

Mar 10, 2025
pulisher
Mar 10, 2025

BofA Raises Price Target on Abbott Laboratories to $150 From $133 -March 10, 2025 at 10:06 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Electroceutical Devices Market Projected To Witness Substantial Growth, 2025-2032: Medtronic plc, Abbott - EIN News

Mar 10, 2025
pulisher
Mar 10, 2025

Abbott Laboratories Stock Analysis: Short-Term Gains vs. Long-Term ChallengesNews and Statistics - IndexBox, Inc.

Mar 10, 2025
pulisher
Mar 10, 2025

3 Reasons to Avoid ABT and 1 Stock to Buy Instead - Yahoo Finance

Mar 10, 2025
pulisher
Mar 10, 2025

Cancer Diagnostics Market Top PlayersGE Healthcare, Abbott - openPR

Mar 10, 2025
pulisher
Mar 10, 2025

Shedd Aquarium receives $10 million pledge from Abbott - Philanthropy News Digest

Mar 10, 2025
pulisher
Mar 09, 2025

Lisa D. Earnhardt Sells 91,167 Shares of Abbott Laboratories (NYSE:ABT) Stock - Defense World

Mar 09, 2025

Finanzdaten der Abbott Laboratories-Aktie (ABT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
medical_devices BSX
$99.22
price up icon 0.32%
medical_devices SYK
$375.91
price up icon 0.65%
medical_devices MDT
$92.21
price down icon 1.22%
medical_devices EW
$70.34
price down icon 0.41%
$82.14
price down icon 0.40%
Kapitalisierung:     |  Volumen (24h):